Status:

COMPLETED

Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy

Lead Sponsor:

All India Institute of Medical Sciences

Collaborating Sponsors:

Dr. Reddy's Laboratories Limited

Conditions:

Chemotherapy Induced Nausea and Vomiting

Eligibility:

All Genders

5-18 years

Phase:

PHASE3

Brief Summary

Chemotherapy induced nausea and vomiting (CINV) is one of the few mostly observed distressing toxicity of cancer treatment. It can occur up to 90% in case of highly emetogenic chemotherapy use. CINV c...

Detailed Description

Population: Children and adolescents (5-18 years) with weight between 15-65 kg receiving highly emetogenic chemotherapy (HEC) - * VAC (vincristine, dactinomycin/Adriamycin, cyclophosphamide) * ABVD ...

Eligibility Criteria

Inclusion

  • All subjects must have a confirmed diagnosis of malignancy and receiving highly emetogenic chemotherapy first time (VAC, ABVD and CDDP/Doxorubicin)
  • Age group 5-18 years with weight between 15-65 kg
  • Children/adolescents and their caregiver who can understand Hindi or English and willing to participate in the study (with written informed consent)

Exclusion

  • Significant organ dysfunction
  • Active infection
  • Pregnancy
  • Uncontrolled medical condition other than malignancy
  • Need for contraindicated concomitant medication
  • Patients receiving chemotherapy other than VAC, ABVD and CDDP/Doxorubicin
  • Treatment with another investigational drug within 4 weeks of study start or prior Aprepitant use
  • Had received or will receive RT to abdomen or pelvis in the week prior to treatment
  • Vomited in the 24 hr prior to treatment
  • Prior exposure to highly emetogenic chemotherapeutics
  • Abnormal lab values (ANC\<1500/mm3, TLC\<3000/mm3, Plt\<100,000/mm3, AST/ALT\> 2.5 times of ULN, bill\>1.5 times of ULN, S.cr\>1.5 times of ULN, patient on systemic steroids

Key Trial Info

Start Date :

August 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2013

Estimated Enrollment :

96 Patients enrolled

Trial Details

Trial ID

NCT01402024

Start Date

August 1 2011

End Date

June 1 2013

Last Update

January 19 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dr. BRA IRCH, AIIMS

New Delhi, National Capital Territory of Delhi, India, 110029